GaryKSchwartzMD

Professor of Medicine Chief, Division of Hematology/Oncology Columbia University Irving Medical Center Deputy Director, Herbert Irving Comprehensive Cancer Center

Join to view full profile

Dr. Schwartz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Schwartz's full profile

Already have an account?

Office
161 Fort Washington Ave
New York, NY 10032
Phone+1 212-305-5098

Education & Training

Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1986 - 1988
Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 1985 - 1986
Zucker School of Medicine at Hofstra/NorthwellInternship, Internal Medicine, 1983 - 1984
Albany Medical CollegeClass of 1983

Certifications & Licensure

FL State Medical License 2021 - Present
NJ State Medical License 2022 - 2025
NY State Medical License 1984 - 2025
OH State Medical License 2023 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Chemotherapy With Raltitrexed and Fluorouracil in Treating Patients With Advanced Colorectal Cancer Start of enrollment: 1995 Apr 01
Completed
Phase 1
Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors Start of enrollment: 1997 Jul 01
Completed
Phase 1
Bryostatin 1 Plus Paclitaxel and Cisplatin in Treating Patients With Advanced Solid Tumors Start of enrollment: 1998 Feb 01
Completed
Phase 1
Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors Start of enrollment: 1999 Jul 01
Completed
Phase 1
Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach Cancer Start of enrollment: 2000 Feb 01
Completed
Phase 2
Flavopiridol and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to Previous Paclitaxel Start of enrollment: 2000 Jul 01
Completed
Phase 2
LY293111 in Treating Patients With Advanced Solid Tumors Start of enrollment: 2000 Jun 01
Completed
Phase 1
Flavopiridol and Irinotecan in Treating Patients With Advanced Solid Tumors Start of enrollment: 2000 Sep 01
Completed
Phase 1
Huang Lian (Chinese Herb) in Treating Patients With Advanced Solid Tumors Start of enrollment: 2000 Oct 01
Completed
Phase 1
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2002 May 01
Completed
Phase 1
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors Start of enrollment: 2002 Apr 01
Completed
Phase 1
UCN-01 and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Start of enrollment: 2002 Jul 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors Start of enrollment: 2002 Jul 01
Completed
Phase 1
Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer Start of enrollment: 2002 Aug 01
Completed
Phase 1
Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Start of enrollment: 2003 Oct 01
Completed
Phase 2
Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors Start of enrollment: 2004 Feb 01
Completed
Phase 1
Safingol and Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2004 Mar 01
Completed
Phase 1
Irinotecan and Flavopiridol in Treating Patients With Advanced Liver Cancer Start of enrollment: 2004 Jun 01
Completed
Phase 2
Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors Start of enrollment: 2006 Mar 01
Completed
Phase 1
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2007 Apr 01
Completed
Phase 2
PTC299 for Treatment of Advanced Cancer Start of enrollment: 2008 Jul 03
Terminated
Phase 1
Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma Start of enrollment: 2009 Nov 01
Completed
Phase 2
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Start of enrollment: 2010 Jun 01
Completed
Phase 1, Phase 2
PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma Start of enrollment: 2010 Sep 23
Completed
Phase 2
RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma Start of enrollment: 2010 Nov 01
Completed
Phase 2
Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients Start of enrollment: 2011 Dec 20
Completed
Phase 1
A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors Start of enrollment: 2012 Nov 27
Terminated
Phase 1, Phase 2
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12
Completed
Phase 3
A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma Start of enrollment: 2013 Jun 01
Completed
Phase 1, Phase 2
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma Start of enrollment: 2013 Aug 01
Terminated
Phase 1, Phase 2
LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma Start of enrollment: 2013 Nov 01
Terminated
Phase 2
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma Start of enrollment: 2013 Oct 23
Completed
Phase 2
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis Start of enrollment: 2014 Mar 21
Completed
Phase 3
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic Start of enrollment: 2014 May 01
Completed
Phase 2
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2015 Sep 14
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

220 citations
γ-Secretase Inhibitors Abrogate Oxaliplatin-Induced Activation of the Notch-1 Signaling Pathway in Colon Cancer Cells Resulting in Enhanced Chemosensitivity
Raymond D. Meng, Christopher C. Shelton, Yue Ming Li, Li-Xuan Qin, Daniel A. Notterman
Cancer Research. 2009-01-15
109 citations
Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma
Federica Catalanotti, David B. Solit, Melissa Pulitzer, Michael F. Berger, Sasinya N. Scott
Clinical Cancer Research. 2013-04-15
87 citations
Therapeutic Implications of the Emerging Molecular Biology of Uveal Melanoma
Mrinali Patel, Elizabeth C Smyth, Paul B. Chapman, Jedd D. Wolchok, Gary K. Schwartz
Clinical Cancer Research. 2011-04-15

Journal Articles

Sorafenib for Advanced and Refractory Desmoid Tumors
Gary Schwartz, MD, The New England Journal of Medicine

Press Mentions

Sequencing Matters – Combination Dabrafenib/Trametinib Versus Nivolumab/Ipilimumab for Advanced BRAF-Mutant Melanoma: The DREAMseq TrialMarch 9th, 2023
Angiosarcoma Research Project Produces Windfall of Druggable InsightsApril 8th, 2020
Six Columbia Cancer Researchers Receive Seed Funding from VelocityJuly 15th, 2019
Join now to see all

Grant Support

P2 - Developing New Strategies For Targeting Pdgfr/Pi3k/Akt Pathways In SarcomaNational Cancer Institute2010–2011
Developing New Strategies For Targeting Mtor And Igf-1r/Pi3k/Akt Pathways In SarcNational Cancer Institute2009–2011
Translational Research Studies In Clinical Trials Of Novel Therapeutics For SarcoNational Cancer Institute2010
Phase II Study Of Imatinib Mesylate In Patients With Inoperable MelanomaFood And Drug Administration2008–2010
Mskcc Clinical Oncology Research Career Development ProgramNational Cancer Institute2006–2010
Laboratory &Clinical Develpmt Of Cell Cycle Active Agents In The Treatmt Of STSNational Cancer Institute2006–2010
Clinical Trials Of Flavopiridol With ChemotherapyNational Cancer Institute2001–2008
Phase I Trial Of Safingol And CisplatinNational Cancer Institute2005–2006
Genetics Of Low Renin HypertensionNational Center For Research Resources2005
Mentoring For New Cancer TherapeauticsNational Cancer Institute2001–2005
Drg1: A Novel Molecular Target For Cancer TherapyNational Cancer Institute2002
Protein Kinase C--A Novel Target For Cancer TherapyNational Cancer Institute1996–2000
Core--BioenergeticsNational Heart, Lung, And Blood Institute1998